Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InspireMDNSPR -0.88%35 Cyclically Adjusted PS Ratio is 0.00 as of Jul. 16, 2026. GuruFocus rates NSPR with a GF Score™ of 35/100 and a GF Value™ of $1.76 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 523 Medical Devices & Instruments companies, InspireMD ranks worse than 191204.4% on this metric.
The historical rank and industry rank for InspireMD's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, InspireMD's highest Cyclically Adjusted PS Ratio was 0.21. The lowest was 0.01. And the median was 0.02.
NSPR's Cyclically Adjusted PS Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.28 * Ranked among companies with meaningful Cyclically Adjusted PS Ratio only.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
InspireMD's adjusted revenue per share data for the three months ended in Mar. 2026 was $0.041. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $145.96 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
InspireMD (NAS:NSPR) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
InspireMD Cyclically Adjusted PS Ratio Related Terms
InspireMD Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for InspireMD's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSPR vs TELA, BDMD, PAVM: Cyclically Adjusted PS Ratio Comparison
For the Medical Devices subindustry, InspireMD's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InspireMD Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where InspireMD's Cyclically Adjusted PS Ratio falls into.
InspireMD Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
InspireMD's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 0.00 mean?
InspireMD (NSPR) has a Cyclically Adjusted PS Ratio of 0.00 as of Jul. 16, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on InspireMD and its competitors. Over the past decade, InspireMD's Cyclically Adjusted PS Ratio has ranged from 0.01 to 0.21. According to the industry distribution chart, InspireMD ranks #999999 out of 523 companies in the Medical Devices & Instruments industry.
Is InspireMD's Cyclically Adjusted PS Ratio too high?
InspireMD's current Cyclically Adjusted PS Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.21. Based on the distribution chart, InspireMD ranks #999999 out of 523 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, InspireMD has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InspireMD's Cyclically Adjusted PS Ratio compare to TELA and BDMD?
According to the Medical Devices & Instruments industry distribution chart, InspireMD ranks #999999 out of 523 companies for Cyclically Adjusted PS Ratio. This places InspireMD in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.28. Historically, InspireMD's own Cyclically Adjusted PS Ratio has ranged from 0.01 to 0.21 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PS Ratio among Medical Devices & Instruments companies is 2.28, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on InspireMD and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PS Ratio is 2.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InspireMD's current Cyclically Adjusted PS Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InspireMD stock overvalued right now?
Based on GuruFocus' analysis, InspireMD (NSPR) is currently considered Possible Value Trap. The stock's GF Value™ is $1.76, compared to a current price of $0.71 — trading 59.7% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 0.00. InspireMD's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For InspireMD (NSPR), the current Cyclically Adjusted PS Ratio is 0.00 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InspireMD (NSPR) Overvalued in 2026?
Based on GuruFocus' analysis, InspireMD stock appears to be undervalued.
The current stock price of $0.71 is trading 59.7% below its estimated GF Value™ of $1.76.
GuruFocus considers InspireMD to be Possible Value Trap.
Key valuation signals for NSPR:
Cyclically Adjusted PS Ratio: 0.00
GF Value™: $1.76 vs. price of $0.71 (59.7% below fair value)
No single metric tells the full story. See the NSPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
35GF Score
Get the complete analysis for NSPR
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSPR has been successfully added to your 
